Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Publication year range
1.
Foot Ankle Surg ; 29(3): 233-238, 2023 Apr.
Article in English | MEDLINE | ID: mdl-36754689

ABSTRACT

BACKGROUND: Metal screws are the most widely used in treating syndesmotic injuries, but failure and the rigidity of the screws can threaten the success of the treatment and increase the cost of care. We have provided an alternative with an olive wire and external fixator(OWEF) used for syndesmotic fixation. METHODS: A retrospective longitudinal follow-up study was conducted. From February 2011 to January 2018, 58 of 72 patients with ankle fractures and associated syndesmotic disruption were treated with either screw or OWEF fixation. The costs, complications, and clinical outcomes using Olerud-Molander score and Visual Analog score in screw and OWEF fixation group were compared. RESULTS: We found the severity of the injury, BMI of the patients and the different fixation methods were determinants of the complications and clinical outcomes. But if no malreduction of the syndesmosis was present, no difference in clinical result was detected. CONCLUSION: The OWEF method appeared to be at least equally functional and effective to screw fixation while maintaining possible lower complication rate. LEVELS OF CLINICAL EVIDENCE: Level 3.


Subject(s)
Ankle Fractures , Olea , Humans , Ankle Fractures/diagnostic imaging , Ankle Fractures/surgery , Follow-Up Studies , Retrospective Studies , Ankle Joint/surgery , Fracture Fixation, Internal/methods , Treatment Outcome , Bone Screws , External Fixators
2.
Chinese Journal of Surgery ; (12): 300-304, 2010.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-254792

ABSTRACT

<p><b>OBJECTIVES</b>To study the relationship between promoter methylation and mRNA expressions of EMP3 and PCDH-gamma-A11 genes in human glioma, and to analyze the regulation mechanism of promoter methylation in the progression of glioma.</p><p><b>METHODS</b>The promoter methylation of EMP3 and PCDH-gamma-A11 was studied by a methylation specific PCR in 88 primary astrocytoma, 10 normal brain tissues and 2 glioma cell lines. The mRNA expressions were detected by real-time PCR in 30 primary glioma and 10 normal brain tissues. The correlations of their promoter methylation, mRNA expressions and clinicopathologic characteristics were analyzed. The promoter methylation were also detected in U251 and SHG-44 cell lines.</p><p><b>RESULTS</b>The promoter methylation of EMP3 was detected in 42 tumors (47.7%) and the methylation of PCDH-gamma-A11 was detected in 76 tumors (86.4%). Their mRNA expressions were all significantly decreased in different pathological grade astrocytomas compared to the normal brain tissues (P < 0.01). Their expressions were suppressed but could be reactivated by 5-aza-deoxycytidine in U251 and SHG-44 cell lines.</p><p><b>CONCLUSIONS</b>The promoter methylation of EMP3 and PCDH-gamma-A11 genes may lead to the down-regulation of their mRNA levels in glioma. The promoter methylation and mRNA expressions of EMP3 and PCDH-gamma-A11 are closely related with the malignant development of glioma. The promoter methylation of the two genes may provide clues to evaluation of glioma malignancy as well as its prognosis. It also gives us an insight for future glioma medical therapy with a demethylating agent.</p>


Subject(s)
Humans , Brain Neoplasms , Genetics , Cadherins , Genetics , Cell Line, Tumor , DNA Methylation , Glioma , Genetics , Membrane Glycoproteins , Genetics , Promoter Regions, Genetic , Genetics , RNA, Messenger , Genetics
3.
Chinese Journal of Traumatology ; (6): 188-190, 2004.
Article in English | WPRIM (Western Pacific) | ID: wpr-270252

ABSTRACT

<p><b>OBJECTIVE</b>To probe the incidence, pathogenesis and clinical characteristics of traumatic subdural hydroma (TSH) developing into chronic subdural hematoma (CSDH).</p><p><b>METHODS</b>We retrospectively analyzed the clinical data of 32 patients with TSH developing into CSDH and reviewed related literature.</p><p><b>RESULTS</b>16.7% of TSH developed into CSDH in this study. The time of evolution was from 22 to 100 days after head injury. All the patients were cured with hematoma drainage.</p><p><b>CONCLUSIONS</b>TSH is one of the origins of CSDH. The clinical characteristics of TSH developing into CSDH follow that the ages of the patients are polarized, that the evolution often happens in the patients with small chronic hydromas and being treated conservatively, that the patients are usually injured deceleratedly and that the accompanying cerebral damage is often very mild.</p>


Subject(s)
Adolescent , Adult , Child , Female , Humans , Male , Middle Aged , Brain Injuries , Chronic Disease , Hematoma, Subdural , Subdural Effusion
SELECTION OF CITATIONS
SEARCH DETAIL
...